Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patients

Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysispatients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24822

Enrollment

114

Registered

2008-06-11

Start date

2008-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Failure: chronisch nierfalen Secondary Hyperparathyroidism: secundaire hyperparathyreoidie Vitamin D: vitamine D Paricalcitol: paricalcitol

Interventions

After randomisation two groups of hemodialysispatients will be separated. Group A gets treated with alfacalcitol and Group B with paricalcitol. After six months will the groups switch.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hemodialysis patients older than 18 years 2. Secundary hyperparathyroidism

Exclusion criteria

Exclusion criteria: 1. Severe hypercalcemia 2. Severe liver failure 3. Digoxin overdose 4. Hypersensitive response to vitamin D or vitamin D overdose

Design outcomes

Primary

Measure	Time frame
Effectiveness: measure the main PTH level	—

Secondary

Measure	Time frame
Security Main Calcium (Ca2+)-level Main Fosfaat (P)-level Main Calicum-Fosfaatproduct (Ca x P) -level Numbers of hypercalcemia episodes Numbers of hyperphosphatemia episodes Numbers of raised Ca x P episodes Bone-alkaline phosphatase (BAP), expressed as a Z-score Costs Total costs of the whole treatment: measuring the oral medication of phosphate-binders and calcimimetics.	—

Contacts

Public ContactJoris J.G Heuvel, van den

Sint Lucas Andreas ziekenhuis Postbus 9243 1006 AE

j.vandenheuvel@slaz.nl+31 (020) 5108911

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)